The emergence of multidrug resistance is a major threat to TB care and control globally. The World Health Organization (WHO) estimates that up to half a million new cases of MDR-TB occur each year worldwide. Currently, the drug Bedaquiline is approved for use as part of a combination drug therapy for the treatment of multidrug-resistant pulmonary tuberculosis when there is no effective treatment regimen.

Streptomycin is an aminoglycoside antibiotic indicated for the treatment of multidrug-resistant mycobacterium tuberculosis and other non-tuberculosis infections. Although the drug Streptomycin was the first antibiotic available to treat mycobacterium tuberculosis, it is now mostly second choice due to resistance and toxicity.

Our country is one of the countries with a high rate of multidrug-resistant tuberculosis in the world. Multidrug resistance makes the treatment of tuberculosis even more difficult, increasing the mortality rate due to tuberculosis. Not only that, multidrug-resistant tuberculosis bacteria can also spread to people around if not detected and controlled early.

Drug-resistant tuberculosis is a dangerous form of tuberculosis with side effects that seriously affect the patient's health. Treatment of drug-resistant tuberculosis is not only costly but also takes longer than that of normal tuberculosis. Therefore, patients need to strictly follow the treatment principles as directed by their doctor.

Combining vitamin C with anti-tuberculosis drugs may shorten treatment time. The results, obtained in mice and tissue cultures in the laboratory, have opened a new direction to solve the difficult problem of treating multidrug-resistant tuberculosis.